Harmony Biosciences Reports Q3 Financial Results on Track to Achieve More Than $1 Billion WAKIX Net Revenue and Announces Strong Multiple-Ascending Dose Data for Its Orexin Agonist BP-205, Supporting Potential Best-in-Class Profile
Harmony Biosciences reported Q3 2026 WAKIX net revenue of $268.9 million, up 12% year-over-year on 400 net patient adds, and reaffirmed full-year guidance of $1.0-$1.04 billion. GAAP net income fell to $48.2 million ($0.81 diluted EPS) from $50.9 million ($0.87) a year ago, driven by cost of product sold rising to 30% of revenue on new Novitium royalties and a $25 million MSN license milestone charge in R&D. Preliminary data from BP-205's 14-day multiple-ascending dose study showed a favorable safety and PK profile supporting once-daily dosing, with Phase 1b data expected Q1 2027 and Phase 2 starts by mid-2027; Pitolisant GR is under FDA review with an April 1, 2027 PDUFA date.
Key figures
- Eps
- 0.81
- Revenue
- 268917000
- Guidance
- Reiterated full-year 2026 WAKIX net revenue of $1.0 billion to $1.04 billion
- Revenue Yoy
- 12%
- Net income
- 48196000
- Rd expense
- 71663000
- Gross profit
- 188231000
- Eps prior year
- 0.87
- Net patient adds
- 400
- Operating income
- 54197000
- Estimated patients
- 9350
- Cost of product sold
- 80686000
- Net income prior year
- 50865000
- Cogs pct revenue prior
- 25%
- Total operating expenses
- 134034000
- Wakix nine month revenue
- 745584000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.